Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals (NASDAQ: CNSP) will host a live moderated video webcast on September 28, 2022, at 1:00 PM ET to discuss its pivotal global study of Berubicin for treating glioblastoma multiforme (GBM). This adaptive, multicenter trial aims to assess the drug’s efficacy and safety in patients with recurrent GBM following standard therapy failure, focusing on overall survival as the primary endpoint. An interim analysis will evaluate safety and efficacy after 30-50% of patients complete the study. The event will allow audience questions.
CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET and archived for 90 days. CNS Pharmaceuticals focuses on developing innovative cancer treatments, including its lead drug Berubicin, which targets brain cancers. The company will also participate in virtual one-on-one meetings with qualified investors during the conference.
CNS Pharmaceuticals reported its Q2 2022 financial results, posting a net loss of approximately $3.6 million, an improvement from $3.8 million in Q2 2021. The company continues to execute on its clinical operations for Berubicin, a drug being evaluated in a pivotal global trial for Glioblastoma Multiforme (GBM). Currently, 23 out of 54 clinical trial sites are operational across the U.S. and Europe, with European enrollment expected soon. The company maintains a cash position of $9.0 million, expected to fund operations into 2023.
CNS Pharmaceuticals (NASDAQ: CNSP) is urging shareholders to vote in favor of two proposals at the upcoming Annual Shareholder Meeting on July 27, 2022. The proposals seek authorization to increase the number of shares available for issuance and allow the Board to conduct a reverse stock split at a ratio between 1-for-2 and 1-for-30. CEO John Climaco emphasized the necessity of these measures to secure financing and maintain the NASDAQ listing amidst challenging market conditions, while stressing that such actions will only be undertaken if truly needed.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced FDA approval for a protocol amendment to its global trial on Berubicin, targeting recurrent glioblastoma multiforme (GBM). The trial has expanded patient eligibility to those who have undergone multiple first-line therapies. With 19 clinical sites currently active and an additional 42 set to open in Europe and the U.S., the company aims to enhance patient access. A non-binding futility analysis will occur after 30-50% of subjects complete six months, without pausing enrollment. Berubicin, noted for crossing the blood-brain barrier, demonstrates potential in treating aggressive brain cancer.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) recently presented an overview of its ongoing clinical trial for Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM), at the ASCO 2022 Annual Meeting. Berubicin, the first anthracycline to cross the blood-brain barrier, demonstrated greater cytotoxicity compared to doxorubicin in GBM cell lines. The ongoing global study involves 243 patients and assesses Berubicin's efficacy against Lomustine. Positive feedback from European regulatory authorities enhances confidence in the trial's design, which aims to address significant unmet medical needs in GBM treatment.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced CEO John Climaco's participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami. A video of the presentation will be available for on-demand viewing for registered attendees. CNS is focused on developing novel treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, which crosses the blood-brain barrier. The company is also advancing the WP1244 drug technology, showcasing promising preclinical results against various cancers.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that its abstract was accepted for presentation at the ASCO 2022 Annual Meeting, taking place from June 3-7, 2022 in Chicago, IL. The poster titled 'Design and initiation of an adaptive, randomized, controlled study of berubicin for recurrent glioblastoma multiforme' will be presented by Dr. Sandra L. Silberman on June 5, 2022. Berubicin is noted as the first anthracycline able to cross the blood-brain barrier and aims to treat aggressive brain cancers. This represents a significant milestone in CNSP's development of innovative cancer therapies.
CNS Pharmaceuticals (CNSP) announced financial results for Q1 2022, reporting a net loss of approximately $2.8 million, down from $3.6 million year-over-year. The company is expanding its Berubicin study in Switzerland, France, and Spain, aiming to enhance patient enrollment in the pivotal trial for glioblastoma multiforme (GBM). Berubicin has received Fast Track and Orphan Drug Designation from the FDA, potentially accelerating its development. CNSP also has cash on hand of around $12.4 million, expected to fund operations into Q1 2023.
CNS Pharmaceuticals (NASDAQ: CNSP) has received regulatory approval from Spain's AEMPS and the Sevilla Ethics Committee for its pivotal study of Berubicin, targeting recurrent glioblastoma multiforme (GBM). This trial aims to evaluate the efficacy and safety of Berubicin, which uniquely crosses the blood-brain barrier. Approximately 243 patients will be randomized to assess Overall Survival, a key FDA-endorsed endpoint. The study includes a planned futility analysis and has received Fast Track Designation from the FDA for expedited review.